Cancer Metastasis Rev
Cancer Metastasis Reviews
0167-7659
1573-7233
Springer US
Boston


2362138
18265945
9127
10.1007/s10555-008-9127-x
Article


The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways

Lu
Xiongbin

1
4

Nguyen
Thuy-Ai

2

Moon
Sung-Hwan

3

Darlington
Yolanda

2

Sommer
Matthias

1

Donehower
Lawrence A.

larryd@bcm.tmc.edu

1
2
3

1
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030 USA 
2
Interdepartmental Graduate Program in Cell and Molecular Biology, Baylor College of Medicine, Houston, TX 77030 USA 
3
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030 USA 
4
Department of Biological Sciences, University of South Carolina, Columbia, SC 29208 USA 

12
2
2008

6
2008

27
2
123
135
© The Author(s) 2008

W
i
p
INK4a
 and ARF. We present evidence that the suppression of p53, p38 MAP kinase, and ATM/ATR signaling pathways by Wip1 are important components of its oncogenicity when it is amplified and overexpressed in human cancers.

Keywords
Wip1
PPM1D
Serine/threonine phosphatase
PP2C
p53
ATM

issue-copyright-statement
© Springer Science+Business Media, LLC 2008




Introduction
a
t
m
a
t
R
cs
DNA
p
k
c
s
1
2
3
4
5
6
5
6
5
6
].
W
i
p
1
, or Wip1, is a major homeostatic regulator of the ATM/ATR-initiated DNA damage response.
5
7
11
INK4a
ARF
12
]. The inhibition of these tumor suppressors is likely to be a major component of the oncogenic activity of this phosphatase.

Discovery and initial characterization of Wip1
13
Wip1
13
Wip1
p53
13
].
14
1
1
13
15
Fig. 1
a
top
bottom
b
) Primary amino acid sequence alignment between human Wip1 and human PP2Cα phosphatase domains is shown. Identical amino acids are highlighted with a black background while conservative amino acid substitutions are indicated with a gray background. The phosphatase domains of the two molecules show 30% identity and 45% similarity




Wip1
16
Wip1
17
16
Wip1
Wip1
16
].

Wip1 is a type 2C phosphatase
18
19
20
21
19
18
20
21
].
2+
2+
18
20
21
1
11
22
23
].
15
24
24
].
11
15
24
25
4
in vitro
in vivo
2
7
9
26
].

Identification of Wip1 targets reveals it to be a homeostatic regulator of the DNA damage response
Wip1 dephosphorylates DNA damage response/repair proteins at TXY motifs
1
1
7
26
27
30
31
Table 1
Identified Wip1 dephosphorylation targets

Protein
a

Motif
Kinase
Protein function
Wip1 effects
p53 effect?
Reference


p38 MAPK
T180
TXY
MKK3/6
Stress response
Dec. kinase activity
Yes (dec.)
11
]

UNG2
T6
TXY
?
Base excision repair
Dec. uracil excision
No
25
]

Chk1
S345
S/TQ
ATR
DNA damage response
Dec. kinase activity
Yes (dec.)
10
]

p53
S15
S/TQ
ATM
DNA damage response
Dec. apoptosis
Yes (dec.)
10
]

Chk2
b

S/T/Q
ATM
DNA damage response
Dec. kinase activity
Yes (dec.)
9
]

ATM
S1981
S/TQ
c

DNA damage response
Dec. kinase activity
Yes (dec.)
7
]

Mdm2
S395
S/TQ
ATM
p53 regulation
Dec. p53 levels
Yes (dec.)
8
]



a
Listed sites are from the human proteins; mouse sites (e.g. p53 S18 or ATM S1987) may be at different amino acid codons
b
Also sites Ser19, Ser33/35, Thr68, and Thr432
c
Activated ATM autophosphorylates itself at S1981; S367 also dephosphorylated by Wip1



TXY motif: p38
11
32
33
28
34
35
11
11
]. Dephosphorylation of Ser33 and Ser46 on p53 was accompanied by reduced p53 transcriptional activation activity and reduced p53-mediated apoptotic function following UV irradiation. Thus, Wip1 inhibits UV-induced phosphorylation of p53 on Ser33 and Ser46 via p38 downregulation, functioning as a mediator in a p53 negative feedback regulatory loop.

TXY motif: UNG2
36
UNG
36
].
In vitro
in vivo
25
37
25
25
38
].


Wip1 dephosphorylates DNA damage response proteins at S/TQ motifs
S/TQ motif: Chk1, Chk2
39
40
41
].
42
43
44
45
46
47
48
].
10
In vitro
In vivo
10
2
26
Fig. 2
Mdm2
Wip1
Wip1
circles
octagons
rectangles
Small circles
Black lines
gray lines
 show later homeostatic events in the damage response




in vitro
in vivo
9
14
49
51
].

S/TQ motif: p53
52
p53
53
p53
54
55
56
].
in vitro
10
]. UV-irradiated cells exhibited reduced p53 Ser15 phosphorylation in the presence of overexpressed Wip1 and greatly augmented and sustained p53 Ser15 phosphorylation in the presence of Wip1 siRNA. As expected, increased Ser15 phosphorylation correlated with increased p53 protein levels in irradiated Wip1 siRNA treated cells.

S/TQ motif: Mdm2
55
31
]. Phosphorylation at this site also inhibits Mdm2 interactions with p53. Thus, p53 is stabilized.
8
49
8
in vitro
in vivo
8
2
).

S/TQ motif: ATM
4
].
Wip1
7
57
] have also shown that Wip1 dephosphorylates human ATM at Ser367 as well as Ser1981. The authors concluded that Wip1 was important in resetting ATM phosphorylation after repair of DNA damage.



Wip1 is an oncogene
58
59
bona fide
INK4A
 signaling pathways would argue that this protein may possess major oncogenic potential.
17
60
Wip1
Wip1
Wip1
Wip1
Wip1
p53
Wip1
p53
Wip1
Mdm2
p53
61
Wip1
62
63
62
Wip1
Wip1
Wip1
63
Wip1
64
65
66
51
67
69
2
2
Wip1
p53
Wip1
p53
p53
Table 2
Human tumors with Wip1 gene amplification and/or overexpression

Organ/Type
DNA/RNA increase
p53 mutation
a

Reference


Breast adenocarcinoma
b
c
)
1/8
 
17
]

 
(16% CNG; ECG)
 
 
62
]

 
(11% CNG; ECG)
1/10
Poorer
64
]

 
d
)
 
 
65
]

Ovarian clear cell adenocarcinoma
(40% CNG; ECG)
 
Poorer
66
]

Neuroblastoma
(92% CNG; 28% O)
2/32
Poorer
67
]

Medulloblastoma
(51% CNG; 88% O)
 
Poorer
70
]

 
(37% CNG; 27% O)
 
 
69
]

Gastric carcinoma
(74% O)
 
 
53
]

Pancreatic adenocarcinoma
(36% CNG)
 
Poorer
68
]



a
Prognosis: “Poorer” indicates individuals with tumors with increased Wip1 copy number and/or expression have significantly poorer prognosis than all individuals with that type of tumor
b
CNG: Wip1 DNA copy number gain (compared to DNA in normal tissues)
c
ECG: increased Wip1 RNA expression significantly correlates with copy number gain
d
O: percentage of tumors with Wip1 RNA overexpression



Wip1
17
60
p53
17
49
]. In contrast to wild-type Wip1, the phosphatase-dead mutant Wip1 (D307A) failed to transform primary fibroblasts.
in vivo
70
Wip1
Wip1
Wip1
70
]. MKK6 activates p38 MAP kinase and thus nullifies the effects of Wip1 dephosphorylation of p38, demonstrating the importance of Wip1 in regulating p38 signaling as well as p53 signaling in this particular model.

Mechanisms of Wip1 oncogenicity
17
49
60
70
2
p53
2
Wip1
Wip1
71
Wip1
 null mice also showed increased susceptibility to pathogens and diminished T- and B-cell function.
Wip1
12
71
Wip1
12
Wip1
Wip1
INK4A
ARF
Wip1
Wip1
12
Wip1
 null MEFs are supported by the fact that Wip1 directly dephosphorylates p38 and p53 and regulators of p53 (ATM, Chk1, Chk2). Since p21 is transcriptionally upregulated by p53, the increase in its levels is attributable to p53 activation.
Wip1
ARF
INK4a
Wip1
12
p53
p53
Wip1
p53
Wip1
Wip1
Wip1
ARF
12
].
12
Wip1
in vivo
Wip1
Wip1
Wip1
Wip1
Wip1
Wip1
Wip1
INK4a
Wip1
Wip1
Wip1
Wip1
−/− MMTV-ErbB2 mice.
57
Wip1
Wip1
Wip1
Wip1
Wip1
Wip1
Wip1
Wip1
14
Wip1
ARF
Wip1
57
]. Thus, overexpression of Wip1 in an oncogenic context could contribute to tumor promotion by inhibiting both p53 and ATM functions.
Wip1
49
Wip1
Wip1
Wip1
Wip1
Wip1
P
 = 0.016). These results suggest that the absence of Wip1 confers a significant degree of resistance to cancer development over the lifespan of the mouse.
Wip1
Wip1
Wip1
Wip1
49
Wip1
5
6
].
3
2
INK4a
Table 3
Evidence that the Wip1 gene is an oncogene

Evidence
References


1. Wip1 specifically inhibits p53 signaling by multiple mechanisms
8
12
17
]

INK4A
)
12
]

3. Wip1 abrogates DNA damage response pathways and cell cycle checkpoints
10
25
51
]

4. Wip1 can transform primary rodent fibroblasts in conjunction with other oncogenes
17
51
62
]

5. Wip1 accelerates tumorigenesis in a mammary tumor susceptible model
72
]

6. Wip1 is amplified and overexpressed in multiple types of human tumors
17
62
64
71
]

7. Wip1 amplification and overexpression is often associated with poorer prognosis
64
66
67
68
70
]

8. Wip1 null primary embryo fibroblasts are resistant to transformation by oncogenes
12
]

9. Wip1 null mice are resistant to spontaneous and oncogene-induced tumors
12
51
59
]






Wip1 as a target for cancer chemotherapeutic approaches
INK4A
ARF
24
24
].
72
72
].
73
] identified six compounds that demonstrated strong inhibition of Wip1 phosphatase activity. However, only two of these compounds showed growth inhibitory activity on cancer cell lines. Of these, one specifically inhibited the growth of cells overexpressing Wip1, an effect that was lost in the presence of the p38 MAP kinase inhibitor SB203580. This indicated that suppression of p38 signaling by Wip1 is likely to be an important component of tumor promotion in some Wip1 overexpressing human cancer cells. The identification of novel Wip1 small molecule inhibitors is an encouraging advance and suggests that this approach merits further consideration for testing in human cancer patients.

Other Wip1 biological functions
Wip1
Wip1
71
74
] did demonstrate a rather unexpected regulatory effect of Wip1 on the progesterone receptor. This study showed that overexpression of Wip1 stimulates steroid receptor activity, by enhancing the intrinsic activity of p160 coactivators such as steroid receptor coactivator-1. One result of this activation is that Wip1 positively regulates the activity of estrogen, progesterone, and androgen receptors. This function appears to be independent of p38 MAPK because SB202190 (a potent p38MAPK inhibitor) is unable to reverse the inhibition of the progesterone receptor activity elicited by reducing Wip1 expression in MCF-7 cells.
Wip1
Wip1
Wip1
71
Wip1
 null mice were more likely to die from influenza virus infection than their normal counterparts.
75
Wip1
Wip1
p53
 null strain, many of the thymic and T cell deficiencies were rescued, indicating that a major component of the Wip1−/− T cell phenotypes were likely to be due to increased p53 activity.

Conclusions, future prospects
Wip1
 gene becomes amplified and upregulated. Why and how this abnormal Wip1 alteration occurs in tumors is unclear, but should be of much interest in future studies.
Many important questions remain to be answered. The structure, catalytic activities and functional domains of Wip1 are still poorly understood. What does the C-terminal non-catalytic domain do? Are pTXpY and pS/pTQ the only target motifs recognized by Wip1 or are there others? And what are the other target proteins? The best guess is that there are likely to be hundreds of targets, if not more. Does Wip1 have other undiscovered functions? And perhaps most importantly, from a disease perspective, how many human cancers exhibit Wip1 overexpression, what are the mechanisms for Wip1-mediated oncogenesis, and how can our knowledge of these mechanisms assist us in designing novel therapies to fight cancer? The answers to these questions in the coming years should result in increased interest in this heretofore little studied protein.


Acknowledgements
This work was supported by an NIH R01 grant (CA100420), a James S. McDonnell Foundation grant to L.A.D. and a D.O.D. Breast Cancer Research Program pre-doctoral fellowship to T.A.N.
Open Access
 This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References
1.
Abraham
R. T.


Cell cycle checkpoint signaling through the ATM and ATR kinases
Genes & Development
2001
15
2177
2196
10.1101/gad.914401

11544175


2.
Shiloh
Y.


ATM and related protein kinases: safeguarding genome integrity
Nature Reviews Cancer
2003
3
155
168
10.1038/nrc1011

12612651


3.
Kim
S. T.

Lim
D. S.

Canman
C. E.

Kastan
M. B.


Substrate specificities and identification of putative substrates of ATM kinase family members
Journal of Biological Chemistry
1999
274
37538
37543
10.1074/jbc.274.53.37538

10608806


4.
Matsuoka
S.

Ballif
B. A.

Smogorzewska
A.

McDonald
E. R.

Hurov
K. E.

Luo
J.



ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage
Science
2007
316
1160
1166
10.1126/science.1140321

17525332


5.
Gorgoulis
V. G.

Vassiliou
L. V.

Karakaidos
P.

Zacharatos
P.

Kotsinas
A.

Liloglou
T.



Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Nature
2005
434
907
913
10.1038/nature03485

15829965


6.
Bartkova
J.

Horejsi
Z.

Koed
K.

Kramer
A.

Tort
F.

Zieger
K.



DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Nature
2005
434
864
870
10.1038/nature03482

15829956


7.
Shreeram
S.

Demidov
O. N.

Hee
W. K.

Yamaguchi
H.

Onishi
N.

Kek
C.



Wip1 phosphatase modulates ATM-dependent signaling pathways
Molecular Cell
2006
23
757
764
10.1016/j.molcel.2006.07.010

16949371


8.
Lu
X.

Ma
O.

Nguyen
T. A.

Jones
S. N.

Oren
M.

Donehower
L. A.



The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop
Cancer Cell
2007
12
342
354
10.1016/j.ccr.2007.08.033

17936559


9.
Fujimoto
H.

Onishi
N.

Kato
N.

Takekawa
M.

Xu
X. Z.

Kosugi
A.



Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase
Cell Death and Differentiation
2006
13
1170
1180
10.1038/sj.cdd.4401801

16311512


10.
Lu
X.

Nannenga
B.

Donehower
L. A.


PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints
Genes & Development
2005
19
1162
1174
10.1101/gad.1291305

15870257


11.
Takekawa
M.

Adachi
M.

Nakahata
A.

Nakayama
I.

Itoh
F.

Tsukuda
H.



p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation
EMBO Journal
2000
19
6517
6526
10.1093/emboj/19.23.6517

11101524


12.
Bulavin
D. V.

Phillips
C.

Nannenga
B.

Timofeev
O.

Donehower
L. A.

Anderson
C. W.



Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway
Nature Genetics
2004
36
343
350
10.1038/ng1317

14991053


13.
Fiscella
M.

Zhang
H.

Fan
S.

Sakaguchi
K.

Shen
S.

Mercer
W. E.



Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner
Proceedings of the National Academy of Sciences of the United States of America
1997
94
6048
6053
10.1073/pnas.94.12.6048

9177166


14.
Yoda
A.

Xu
X. Z.

Onishi
N.

Toyoshima
K.

Fujimoto
H.

Kato
N.



Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1
Journal of Biological Chemistry
2006
281
24847
24862
10.1074/jbc.M600403200

16798742


15.
Yamaguchi
H.

Minopoli
G.

Demidov
O. N.

Chatterjee
D. K.

Anderson
C. W.

Durell
S. R.



Substrate specificity of the human protein phosphatase 2Cdelta, Wip1
Biochemistry
2005
44
5285
5294
10.1021/bi0476634

15807522


16.
Choi
J.

Appella
E.

Donehower
L. A.


The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene
Genomics
2000
64
298
306
10.1006/geno.2000.6134

10756097


17.
Bulavin
D. V.

Demidov
O. N.

Saito
S.

Kauraniemi
P.

Phillips
C.

Amundson
S. A.



Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity
Nature Genetics
2002
31
210
215
10.1038/ng894

12021785


18.
Barford
D.

Das
A. K.

Egloff
M. P.


The structure and mechanism of protein phosphatases: insights into catalysis and regulation
Annual Review of Biophysics and Biomolecular Structure
1998
27
133
164
10.1146/annurev.biophys.27.1.133

9646865


19.
Moorhead
G. B.

Trinkle-Mulcahy
L.

Ulke-Lemee
A.


Emerging roles of nuclear protein phosphatases
Nature Reviews Molecular Cell Biology
2007
8
234
244
10.1038/nrm2126

17318227


20.
Barford
D.


Molecular mechanisms of the protein serine/threonine phosphatases
Trends in Biochemical Sciences
1996
21
407
412
10.1016/S0968-0004(96)10060-8

8987393


21.
Jackson
M. D.

Denu
J. M.


Molecular reactions of protein phosphatases—insights from structure and chemistry
Chemical Reviews
2001
101
2313
2340
10.1021/cr000247e

11749375


22.
Takekawa
M.

Maeda
T.

Saito
H.


Protein phosphatase 2Calpha inhibits the human stress-responsive p38 and JNK MAPK pathways
EMBO Journal
1998
17
4744
4752
10.1093/emboj/17.16.4744

9707433


23.
Hanada
M.

Kobayashi
T.

Ohnishi
M.

Ikeda
S.

Wang
H.

Katsura
K.



Selective suppression of stress-activated protein kinase pathway by protein phosphatase 2C in mammalian cells
FEBS Letters
1998
437
172
176
10.1016/S0014-5793(98)01229-0

9824284


24.
Yamaguchi
H.

Durell
S. R.

Feng
H.

Bai
Y.

Anderson
C. W.

Appella
E.


Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1
Biochemistry
2006
45
13193
13202
10.1021/bi061356b

17073441


25.
Lu
X.

Bocangel
D.

Nannenga
B.

Yamaguchi
H.

Appella
E.

Donehower
L. A.


The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair
Molecular Cell
2004
15
621
634
10.1016/j.molcel.2004.08.007

15327777


26.
Lu
X.

Nguyen
T. A.

Donehower
L. A.


Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D
Cell Cycle
2005
4
1060
1064

15970689


27.
Siliciano
J. D.

Canman
C. E.

Taya
Y.

Sakaguchi
K.

Appella
E.

Kastan
M. B.


DNA damage induces phosphorylation of the amino terminus of p53
Genes & Development
1997
11
3471
3481
10.1101/gad.11.24.3471

9407038


28.
Bulavin
D. V.

Saito
S.

Hollander
M. C.

Sakaguchi
K.

Anderson
C. W.

Appella
E.



Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation
EMBO Journal
1999
18
6845
6854
10.1093/emboj/18.23.6845

10581258


29.
Liu
Q.

Guntuku
S.

Cui
X. S.

Matsuoka
S.

Cortez
D.

Tamai
K.



Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint
Genes & Development
2000
14
1448
1459
10.1101/gad.840500

10859164


30.
Shieh
S. Y.

Ahn
J.

Tamai
K.

Taya
Y.

Prives
C.


The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
Genes & Development
2000
14
289
300

10673501


31.
Maya
R.

Balass
M.

Kim
S. T.

Shkedy
D.

Leal
J. F.

Shifman
O.



ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage
Genes & Development
2001
15
1067
1077
10.1101/gad.886901

11331603


32.
Derijard
B.

Raingeaud
J.

Barrett
T.

Wu
I. H.

Han
J.

Ulevitch
R. J.



Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms
Science
1995
267
682
685
10.1126/science.7839144

7839144


33.
Raingeaud
J.

Gupta
S.

Rogers
J. S.

Dickens
M.

Han
J.

Ulevitch
R. J.



Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine
Journal of Biological Chemistry
1995
270
7420
7426
10.1074/jbc.270.13.7420

7535770


34.
She
Q. B.

Chen
N.

Dong
Z.


ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation
Journal of Biological Chemistry
2000
275
20444
20449
10.1074/jbc.M001020200

10781582


35.
Huang
C.

Ma
W. Y.

Maxiner
A.

Sun
Y.

Dong
Z.


p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389
Journal of Biological Chemistry
1999
274
12229
12235
10.1074/jbc.274.18.12229

10212189


36.
Krokan
H. E.

Drablos
F.

Slupphaug
G.


Uracil in DNA—occurrence, consequences and repair
Oncogene
2002
21
8935
8948
10.1038/sj.onc.1205996

12483510


37.
Rual
J. F.

Venkatesan
K.

Hao
T.

Hirozane-Kishikawa
T.

Dricot
A.

Li
N.



Towards a proteome-scale map of the human protein-protein interaction network
Nature
2005
437
1173
1178
10.1038/nature04209

16189514


38.
Lu
X.

Nguyen
T. A.

Appella
E.

Donehower
L. A.


Homeostatic regulation of base excision repair by a p53-induced phosphatase: Linking stress response pathways with DNA repair proteins
Cell Cycle
2004
3
1363
1366

15539943


39.
Bartek
J.

Lukas
J.


Chk1 and Chk2 kinases in checkpoint control and cancer
Cancer Cell
2003
3
421
429
10.1016/S1535-6108(03)00110-7

12781359


40.
Zhao
H.

Piwnica-Worms
H.


ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1
Molecular Cell Biology
2001
21
4129
4139
10.1128/MCB.21.13.4129-4139.2001

Zhao, H., & Piwnica-Worms, H. (2001). ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Molecular Cell Biology, 21, 4129–4139. 

41.
Karlsson-Rosenthal
C.

Millar
J. B.


Cdc25: mechanisms of checkpoint inhibition and recovery
Trends in Cell Biology
2006
16
285
292
10.1016/j.tcb.2006.04.002

16682204


42.
Melchionna
R.

Chen
X. B.

Blasina
A.

McGowan
C. H.


Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1
Nature Cell Biology
2000
2
762
765
10.1038/35036406

11025670


43.
Matsuoka
S.

Rotman
G.

Ogawa
A.

Shiloh
Y.

Tamai
K.

Elledge
S. J.


in vivo
in vitro

Proceedings of the National Academy of Sciences of the United States of America
2000
97
10389
10394
10.1073/pnas.190030497

10973490


44.
Ahn
J. Y.

Schwarz
J. K.

Piwnica-Worms
H.

Canman
C. E.


Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation
Cancer Research
2000
60
5934
5936

11085506


45.
Gatei
M.

Sloper
K.

Sorensen
C.

Syljuasen
R.

Falck
J.

Hobson
K.



Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation
Journal of Biological Chemistry
2003
278
14806
14811
10.1074/jbc.M210862200

12588868


46.
Hirao
A.

Cheung
A.

Duncan
G.

Girard
P. M.

Elia
A. J.

Wakeham
A.



Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner
Molecular Cell Biology
2002
22
6521
6532
10.1128/MCB.22.18.6521-6532.2002

Hirao, A., Cheung, A., Duncan, G., Girard, P. M., Elia, A. J., Wakeham, A., et al. (2002). Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Molecular Cell Biology, 22, 6521–6532. 

47.
Cuadrado
M.

Martinez-Pastor
B.

Fernandez-Capetillo
O.


“ATR activation in response to ionizing radiation: still ATM territory”
Cell Division
2006
1
7
10.1186/1747-1028-1-7

16759429


48.
Jazayeri
A.

Falck
J.

Lukas
C.

Bartek
J.

Smith
G. C.

Lukas
J.



ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
Nature Cell Biology
2006
8
37
45
10.1038/ncb1337

16327781


49.
Nannenga
B.

Lu
X.

Dumble
M.

Maanen
M.

Nguyen
T. A.

Sutton
R.



Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice
Molecular Carcinogenesis
2006
45
594
604
10.1002/mc.20195

16652371


50.
Oliva-Trastoy
M.

Berthonaud
V.

Chevalier
A.

Ducrot
C.

Marsolier-Kergoat
M. C.

Mann
C.



The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase
Oncogene
2007
26
1449
1458
10.1038/sj.onc.1209927

16936775


51.
Fuku
T.

Semba
S.

Yutori
H.

Yokozaki
H.


Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma
Pathology International
2007
57
566
571
10.1111/j.1440-1827.2007.02140.x

17685927


52.
Horn
H. F.

Vousden
K. H.


Coping with stress: Multiple ways to activate p53
Oncogene
2007
26
1306
1316
10.1038/sj.onc.1210263

17322916


53.
Olivier
M.

Hussain
S. P.

Caron de Fromentel
C.

Hainaut
P.

Harris
C. C.


TP53 mutation spectra and load: A tool for generating hypotheses on the etiology of cancer
IARC Scientific Publications
2004
157
247
270

15055300


54.
Donehower
L. A.

Harvey
M.

Slagle
B. L.

McArthur
M. J.

Montgomery
C. A.

Butel
J. S.



Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Nature
1992
356
215
221
10.1038/356215a0

1552940


55.
Bond
G. L.

Hu
W.

Levine
A. J.


MDM2 is a central node in the p53 pathway: 12 years and counting
Current Cancer Drug Targets
2005
5
3
8
10.2174/1568009053332627

15720184


56.
Shieh
S. Y.

Ikeda
M.

Taya
Y.

Prives
C.


DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Cell
1997
91
325
334
10.1016/S0092-8674(00)80416-X

9363941


57.
Shreeram
S.

Hee
W. K.

Demidov
O. N.

Kek
C.

Yamaguchi
H.

Fornace
A. J.



Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase
Journal of Experimental Medicine
2006
203
2793
2799
10.1084/jem.20061563

17158963


58.
Ostman
A.

Hellberg
C.

Bohmer
F. D.


Protein-tyrosine phosphatases and cancer
Nature Reviews Cancer
2006
6
307
320
10.1038/nrc1837

16557282


59.
Arroyo
J. D.

Hahn
W. C.


Involvement of PP2A in viral and cellular transformation
Oncogene
2005
24
7746
7755
10.1038/sj.onc.1209038

16299534


60.
Li
J.

Yang
Y.

Peng
Y.

Austin
R. J.

Eyndhoven
W. G.

Nguyen
K. C.



Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23
Nature Genetics
2002
31
133
134
10.1038/ng888

12021784


61.
Momand
J.

Jung
D.

Wilczynski
S.

Niland
J.


The MDM2 gene amplification database
Nucleic Acids Research
1998
26
3453
3459
10.1093/nar/26.15.3453

9671804


62.
Rauta
J.

Alarmo
E. L.

Kauraniemi
P.

Karhu
R.

Kuukasjarvi
T.

Kallioniemi
A.


The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours
Breast Cancer Research and Treatment
2006
95
257
263
10.1007/s10549-005-9017-7

16254685


63.
Yu
E.

Ahn
Y. S.

Jang
S. J.

Kim
M. J.

Yoon
H. S.

Gong
G.



Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers
Breast Cancer Research and Treatment
2007
101
269
278
10.1007/s10549-006-9304-y

16897432


64.
Hirasawa
A.

Saito-Ohara
F.

Inoue
J.

Aoki
D.

Susumu
N.

Yokoyama
T.



Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets
Clinical Cancer Research
2003
9
1995
2004

12796361


65.
Saito-Ohara
F.

Imoto
I.

Inoue
J.

Hosoi
H.

Nakagawara
A.

Sugimoto
T.



PPM1D is a potential target for 17q gain in neuroblastoma
Cancer Research
2003
63
1876
1883

12702577


66.
Loukopoulos
P.

Shibata
T.

Katoh
H.

Kokubu
A.

Sakamoto
M.

Yamazaki
K.



Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome
Cancer Science
2007
98
392
400
10.1111/j.1349-7006.2007.00395.x

17233815


67.
Ehrbrecht
A.

Muller
U.

Wolter
M.

Hoischen
A.

Koch
A.

Radlwimmer
B.



Comprehensive genomic analysis of desmoplastic medulloblastomas: Identification of novel amplified genes and separate evaluation of the different histological components
Journal of Pathology
2006
208
554
563
10.1002/path.1925

16400626


68.
Mendrzyk
F.

Radlwimmer
B.

Joos
S.

Kokocinski
F.

Benner
A.

Stange
D. E.



Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma
Journal of Clinical Oncology
2005
23
8853
8862
10.1200/JCO.2005.02.8589

16314645


69.
Castellino, C., De Bortoli, M., Moon S. H., Lu, X., Skapura, D. G., Lin, L. L., et al. (2007). Medulloblastomas overexpress the p53-Inactivating oncogene Wip1/PPM1D. J. Neuro-Onc. (in press).

70.
Demidov
O. N.

Kek
C.

Shreeram
S.

Timofeev
O.

Fornace
A. J.

Appella
E.



The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis
Oncogene
2007
26
2502
2506
10.1038/sj.onc.1210032

17016428


71.
Choi
J.

Nannenga
B.

Demidov
O. N.

Bulavin
D. V.

Cooney
A.

Brayton
C.



Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control
Molecular Cell Biology
2002
22
1094
1105
10.1128/MCB.22.4.1094-1105.2002

Choi, J., Nannenga, B., Demidov, O. N., Bulavin, D. V., Cooney, A., Brayton, C., et al. (2002). Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Molecular Cell Biology, 22, 1094–1105. 

72.
Belova
G. I.

Demidov
O. N.

Fornace
A. J.

Bulavin
D. V.


Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis
Cancer Biology and Therapy
2005
4
1154
1158

16258255


73.
Rayter, S., Elliott, R., Travers, J., Rowlands, M. G., Richardson, T. B., Boxall, K., et al. (2007). A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene (in press).

74.
Proia
D. A.

Nannenga
B. W.

Donehower
L. A.

Weigel
N. L.


Dual roles for the phosphatase PPM1D in regulating progesterone receptor function
Journal of Biological Chemistry
2006
281
7089
7101
10.1074/jbc.M511839200

16352595


75.
Schito
M. L.

Demidov
O. N.

Saito
S.

Ashwell
J. D.

Appella
E.


Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation
Journal of Immunology
2006
176
4818
4825

Schito, M. L., Demidov, O. N., Saito, S., Ashwell, J. D., & Appella, E. (2006). Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation. Journal of Immunology, 176, 4818–4825. 


Abbreviations
ARF
alternate reading frame of the ink4a locus


ATM
ataxia telangiectasia mutated


ATR
ataxia telangiectasia and Rad3-related


BER
base excision repair


BRCA1
breast cancer gene 1


Chk1 and 2
checkpoint kinases 1 and 2


DNA-PK
DNA-dependent protein kinase


MAPK
mitogen-activated protein kinase


MEF
mouse embryo fibroblast


Mdm2
mouse double minute 2


MKK6
MAPK kinase 6


MMTV
mouse mammary tumour virus


PIKK
phosphoinositide-3-kinase-related kinase


PP2C
protein phosphatase type 2C


RB
retinoblastoma


UNG2
uracil DNA glycosylase 2


Wip1
wild-type p53-induced phosphatase 1


Wnt
wingless/INT






